Quinazoline derivatives

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/517 (2006.01) A61P 35/02 (2006.01) A61P 37/06 (2006.01) C07D 239/94 (2006.01)

Patent

CA 2342503

The invention provides novel JAK-3 inhibitors that are useful for treating leukemia and lymphoma. The compounds are also useful to treat or prevent skin cancer, as well as sunburn and UVB-induced skin inflammation. In addition, the compounds of the present invention prevent the immunosuppressive effects of UVB radiation, and are useful to treat or prevent autoimmune diseases, inflammation, and transplant rejection. The invention also provides pharmaceutical compositions comprising compounds of the invention, as well as therapeutic methods for their use.

L'invention concerne de nouveaux inhibiteurs de JAK-3, utiles pour le traitement de la leucémie et des lymphomes. Ces composés sont également utiles pour le traitement ou la prévention des cancers de la peau ainsi que des inflammations cutanées induites par les coups de soleil et les UVB. De plus, ces composés permettent d'éviter les effets immunosuppresseurs du rayonnement UVB et sont utiles pour le traitement ou la prévention des maladies auto-immunes, des inflammations et des rejets de greffes. L'invention concerne en outre des compositions pharmaceutiques contenant ces composants ainsi que des traitements associés.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Quinazoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinazoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline derivatives will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1945991

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.